Volociximab

Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs).

Volociximab (20, 40, 80, 160, 320 nM) specifically targets integrin α5β1 (K_d=0.367 nM), but not integrin α5α5 or β1β1^[1].
Volociximab (0.01-100 nM; 4 d) inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVEC) (IC₅₀=0.2-0.5 nM) and (10 μg/mL; 16 h) induces apoptosis in schizogenic but not senescent Huvecs^[1].
Volociximab (0.067-67 nM; 6 d) inhibits 0.1 μg/mL VEGF and/or bFGF induced HUVEC angiogenesis in vitro^[1].

Volociximab (300 μg/eye; intravitreal injection; once weekly for 4 weeks) has well tolerance and inhibits angiogenesis in laser induced choroidal neovascularization (CNV) of cynomolgus monkey model^[1].
Volociximab (10 mg/kg; i.v.; twice weekly for 3 weeks) suppresses tumor progress in rabbits VX2 model^[2].

References:
[1]. Bhaskar V, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs. 2008 Feb;26(1):7-12.
[2]. Ramakrishnan V, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.